Just another Daily Blogs News weblog
… an agreement to commercialize Viread for the treatment of chronic HBV infection in adults in … of first-line combination therapy with ambrisentan and tadalafil in subjects with PAH), will evaluate first-line … of resistant hypertension. In December, the Anti-Infective Drugs Advisory Committee of the U.S. Food and …
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results

Related posts:

Get News Headline on the motion